Summit Therapeutics Inc. 8-K

What Happened

• Summit Therapeutics Inc. announced its financial results and operational progress for the quarter ended March 31, 2026 by issuing a press release dated April 30, 2026.
• The press release was furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference into the filing. The report was signed by Manmeet S. Soni, Chief Operating Officer, Chief Financial Officer and Director, as the principal financial officer.

Key Details

• Filing date: April 30, 2026.
• Quarter covered: quarter ended March 31, 2026 (Q1 2026).
• Disclosure: Press release announcing quarterly results and operational progress (Exhibit 99.1).
• Form 8-K signed by Manmeet S. Soni (COO, CFO and Director).

Why It Matters

• This 8-K provides Summit’s official quarterly update on earnings, revenue and operational milestones for Q1 2026 — primary information investors use to assess near‑term performance.
• Investors should review the furnished press release (Exhibit 99.1) for the specific financial figures, cash position, and operational details that could affect valuation or trading decisions.